HER2/neu in tissue; HER2/Neu (erbB2) protein expression (H2N Oncosite)

From Aaushi
Jump to navigation Jump to search

Pathology

  • overexpression of HER2 (at protein level) in 25% of breast cancer
  • overexpression predicts more aggressive disease

Indications

Laboratory

  • ~20% of tests for HER2 protein expression
  • LOINC: 18474-7, 31150-6, 32996-1, 42914-2, 48675-3, 48676-1, 49683-6, 51981-9

Methods

More general terms

More specific terms

Additional terms

References

  1. The NCCN Breast Cancer Clinical Practice Guidelines in Oncology (Version 2.2010) 2010 National Comprehensive Cancer Network, Inc.
  2. Wolff AC, Hammond EH, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guidelines recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007;25:118-145. PMID: https://www.ncbi.nlm.nih.gov/pubmed/17159189 Corresponding NGC guideline withdrawn Dec 2012
  3. ARUOP consult: ERBB2 (HER2/neu) (HercepTest) Testing https://arupconsult.com/ati/erbb2-her2neu-herceptest-testing
    HercepTest Tissue Assay, Paraffin Laboratory Test Directory ARUP: http://www.aruplab.com/guides/ug/tests/0049174.jsp
  4. Wolff AC et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update. J Clin Oncol 2013 Nov 1; 31:3997 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/24101045 <Internet> http://jco.ascopubs.org/content/31/31/3997